ArticleFrontiers in medicine2025
Case Report: Massive emphysematous pyelonephritis with short-term relapse.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Emphysematous pyelonephritis (EPN) is a rare but aggressive infectious disease that lacks specificity in its early stages and tends to progress to life-threatening septic shock in a short period of time. Its diagnosis is based on imaging tests, and treatment requires a combination of staging and risk factors. Case presentation: We report a case of emphysematous pyelonephritis in a patient with massive emphysema of the left kidney (the longest diameter up to 51 mm) on CT. After multidisciplinary consultation, the patient underwent CT-guided percutaneous drainage combined with targeted antibiotic therapy, and was discharged from the hospital with improvement of the condition. However, relapse of symptoms occurred after 1 day of discharge from the hospital, prompting readmission. After an additional 7-day course of antibiotic therapy, the patient recovered completely with no recurrence during 1-month follow-up. Conclusion: Staged diagnosis and individualized therapeutic measures are key to the prognosis of this disease. Despite advances in therapeutic techniques, the risk of relapse is still high, and a comprehensive assessment of infection control is recommended for discharge from the hospital, with intensive follow-up to improve the prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.